ProCE Banner Activity

KEYNOTE-604 Final Analysis: Addition of Pembrolizumab to Etoposide and Platinum in Extensive-Stage SCLC

Slideset Download
Conference Coverage
Pembrolizumab added to first-line therapy with etoposide and platinum chemotherapy for extensive-stage SCLC significantly improved PFS in the final analysis of KEYNOTE-604.

Released: June 01, 2020

Expiration: May 31, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc.

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono